route of administration: intravitreal injection

4 trials

Sponsors

Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences, Intas Pharmaceuticals Ltd Biopharma Division, DEPARTMENT OF OPHTHALMOLOGY REGIONAL INSTITUTE OF OPHTHALMOLOGY AND GOVERNMENT OPHTHALMIC HOSPITAL

Conditions

Diabetic macular edemaHealth Condition 1: H00-H59- Diseases of the eye and adnexa Health Condition 2: H36- Retinal disorders in diseases classified elsewhereHealth Condition 1: H353- Degeneration of macula and posterior poleWet age-related macular degeneration

Phase 2

Phase Ib / IIa clinical study on the safety and efficacy of BAT5906 injection in patients with diabetic macular edema

Active, not recruitingChiCTR2000032727

Beijing Union Medical College Hospital, Chinese Academy of Medical SciencesDiabetic macular edema

Start: 2020-07-01Updated: 2020-05-11

Phase II Clinical Study on the Efficacy and Safety of BAT5906 Injection in Patients With Wet Age-Related Macular Degeneration

Active, not recruitingChiCTR2000032723

Beijing Union Medical College Hospital, Chinese Academy of Medical SciencesWet age-related macular degeneration

Start: 2020-07-01Updated: 2020-05-11

Which is Better? Combined or Sequential approach of Cataract Surgery and Bevacizumab for patients with both Cataract and Diabetic Macular Edema problem

Active, not recruitingCTRI/2024/12/078209

DEPARTMENT OF OPHTHALMOLOGY REGIONAL INSTITUTE OF OPHTHALMOLOGY AND GOVERNMENT OPHTHALMIC HOSPITALHealth Condition 1: H00-H59- Diseases of the eye and adnexa Health Condition 2: H36- Retinal disorders in diseases classified elsewhere

Target: 27Updated: 2025-02-03

Phase 3

A Study of Ranibizumab in Patients

Active, not recruitingCTRI/2021/02/031050

Intas Pharmaceuticals Ltd Biopharma DivisionHealth Condition 1: H353- Degeneration of macula and posterior pole

Target: 546Updated: 2026-03-02